Pfizer/BioNTech Covid-19 vaccine could be ready by mid-October, but there are still 'unknowns'. (CNN)

More reads

• CRO market to recover, using 'hybrid trials,' with revenue hitting $64B by 2024. (FierceBiotech)
• Pfizer/BioNTech Covid-19 vaccine could be ready by mid-October, but there are still 'unknowns'. (CNN) 
• Mylan to pay equivalent of $757 million to buy Aspen's Europe thrombosis business. (MarketWatch)